www.hivandhepatitis.com

IAS 2017: New HIV Infections Halved as Treatment Scales Up in Swaziland

New HIV infections have been cut in half in Swaziland since 2011, at the same time as the proportion of people on antiretroviral treatment with fully suppressed viral load has doubled, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris. It is the first direct evidence that expanding HIV treatment results in fewer HIV infections in a country with a major epidemic, researchers said.

Read more:

IAS 2017: IAS Conference on HIV Science Starts Sunday in Paris

The 9th International AIDS Society (IAS) Conference on HIV Science will take place July 23-26 at the Palais des Congrèsin Paris. HIVandHepatitis.com and aidsmap will be providing joint on-site coverage next week. Follow breaking news via @HIVandHeptitis on Twitter. IAS will be webcasting plenary sessions and daily press conferences.

Read more:

IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study

A sub-study of the French Ipergay trial of "on-demand" pre-exposure prophylaxis (PrEP) has found that PrEP was just as effective for participants who had sex less often than average, and so took PrEP less often, as long as they did take it when it was needed. The analysis was presented by trial statistician Guillemette Antoni at the 9th International AIDS Society Conference (IAS 2017) conference this week in Paris.

Read more:

HR17: Combining Drug Addiction Treatment and Perinatal HIV Prevention Leads to Good Outcomes

An integrated program offering medication-assisted drug addiction treatment and services aimed at preventing mother-to-child HIV transmission led to improved outcomes for opioid-dependent HIV-positive mothers and their babies, according to a presentation at the 25th Harm Reduction International Conference this month in Montreal.

Read more:

IAS 2017: South African Child Has Controlled HIV Off Treatment for 8.5 Years

A 9-year-old South African child who was diagnosed with HIV infection at 1 month of age and received HIV treatment for 40 weeks during infancy has suppressed the virus without anti-HIV drugs for 8 and a half years, scientists reported this week at the 9th IAS Conference on HIV Science (IAS 2017) in Paris.

Read more:

Coverage of the 2017 Pediatric Academic Societies Meeting

HIVandHepatitis.com coverage of the 2017 Pediatric Academic Societies Meeting, May 6-9, 2017, in San Francisco.

• Many Doctors Wary of Providing PrEP for Young Patients
• Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C
• Children on Immunosuppressive Therapy May Lose Hepatitis B Vaccine Protection 
• Vaccine Reduces Human Papillomavirus Prevalence Among Young Women
• New Approaches Help Babies with Opioid Withdrawal Syndrome

IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report

On July 18 the Treatment Action Group (TAG) announced the launch of its latest overview of investigational therapies for HIV, hepatitis C virus (HCV), and tuberculosis (TB).

Read more:

Coverage of the 2017 Harm Reduction International Conference

HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.

Full coverage listing

HR17 website

5/31/17